Short Summary
The PTAB initiated a sua sponte Director Review of an IPR involving Sinclair Pharma and others versus Hydrafacial, staying the proceeding after the ITC affirmed the claims’ validity and commercial success.
Detailed Summary
In a Director Review proceeding (IPR2025-00145) the PTAB examined a petition by Sinclair Pharma and affiliated entities to challenge Hydrafacial's patent 11,865,287 B2. The patent owner argued that the Board had waived its right to present discretionary denial arguments under 35 U.S.C. § 314(a) and pointed to an International Trade Commission investigation that found the challenged claims were not invalid and that the products enjoyed commercial success. Relying on the ITC findings and precedent, the Board deemed a sua sponte Director Review appropriate and stayed the IPR pending a future opinion, effectively pausing the inter partes review.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Samsung Electronics Co., Ltd. et al. vs Netlist, Inc. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Yangtze Memory Technologies Company, Ltd. et al.vsMicron Technology, Inc. et al.
Yangtze Memory Technologies petitions the PTAB to invalidate 18 claims of Micron's 3D NAND patent, arguing anticipation and obviousness over four prior‑art references. The petition seeks institution and cancellation of the claims.
Microsoft CorporationvsSterling Computers Corporation
The PTAB granted institution for Microsoft's IPR against Sterling Computers, finding a reasonable likelihood of obviousness for at least one claim (Claim 13). The Board adopted a construction of 'relational references' as simple pointers, rejecting the Patent Owner's requirement for a full relational model.
Harbor Freight Tools USA, Inc. et al.vsChampion Power Equipment, Inc.
Harbor Freight and Champion Power filed a joint request asking the PTAB to keep their settlement agreement confidential and separate from the patent file in IPR2025-00805.
Capital One, N.A. et al.vsWapp Tech Corp. et al.
Capital One challenges the PTAB Director’s denial of institution for patent 8,924,192, asserting statutory violations and procedural defects. The petition highlights failure to consider required briefing, lack of a three‑member panel, and missing APA compliance. It seeks vacatur of the decision and a proper institution ruling.
Imperative Care, Inc.vsInari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s hemostasis valve patent (U.S. Patent 11,697,012) on all nine claims after finding the challenger, Imperative Care, showed a reasonable likelihood of prevailing. The dispute centers on claim construction of “filament” and alleged anticipation/obviousness over prior‑art references.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.